Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dantrolene low-volume - Eagle Pharmaceuticals

Next Previous
X
Search
Drug Profile

Dantrolene low-volume - Eagle Pharmaceuticals

Alternative Names: Dantrolene; Dantrolene sodium; EA 111; EP-4104; Ryanodex

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyotropic Therapeutics
  • Developer Eagle Pharmaceuticals; NorthShore University HealthSystem; University of Pennsylvania
  • Class Antidementias; Antipyretics; Antispastics; Antivirals; Furans; Hydantoins; Imidazolidines; Muscle relaxants; Neuroprotectants; Nitrophenols; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fever; Chronic brain damage; Wounds; Wolfram syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever
  • Phase II Chemically-induced disorders
  • Preclinical Chronic brain damage
  • No development reported Alzheimer's disease; COVID 2019 infections; Traumatic brain injuries
  • Discontinued Wounds

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Injection, Suspension)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Intranasal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top